Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sets New 12-Month High – Here’s What Happened

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) shares hit a new 52-week high on Tuesday . The company traded as high as $47.4750 and last traded at $47.4750, with a volume of 200 shares changing hands. The stock had previously closed at $47.35.

Wall Street Analyst Weigh In

BIOVF has been the topic of a number of recent analyst reports. BNP Paribas Exane raised shares of Swedish Orphan Biovitrum to an “outperform” rating in a research report on Tuesday, February 10th. Barclays reaffirmed an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, February 24th. Finally, Danske downgraded shares of Swedish Orphan Biovitrum to a “hold” rating in a research report on Thursday, February 19th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.59 and a current ratio of 0.90. The company has a market capitalization of $16.90 billion, a PE ratio of 158.25 and a beta of 0.34. The company’s 50-day simple moving average is $40.22 and its 200-day simple moving average is $37.13.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last issued its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.07. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 17.23%. The company had revenue of $755.76 million for the quarter, compared to the consensus estimate of $749.76 million.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.